Huang Tong-Hai, Wang Zheng, Li Qing, Li Fu-Rong, Qi Hui, Zhou Han-Xin
Department of Thoracic Surgery, Shenzhen People's Hospital, The 2nd Clinical Medical College of Jinan University, Shenzhen 518020, China.
Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):676-80.
To investigate the feasibility and clinical significance of detection of circulating tumor cells (CTCs) in peripheral blood of NSCLC patients by lung cancer cell immunomagnetic enrichment and detection kit.
Four groups of patients (Group A: 18 cases with stage I lung cancer; Group B: 33 cases with stage II - IV lung cancer; Group C: 20 cases with benign pulmonary diseases; Group D: 20 healthy volunteers) were enrolled for detection of CTCs using the lung cancer cell enrichment and detection kit developed by ourselves, and compared with the results obtained using simple ICC method and the detection of CK19 mRNA and LUNX mRNA using nested PCR as control.
By using lung cancer cell enrichment and detection kit, it was revealed that the detection rates of CK positive cells were 33.3%, 60.6%, 0% and 0% in Group A, B, C and D, respectively. By using nested RT-PCR, the rates of positive expression of CK19 mRNA were 38.9%, 63.6%, 20.0% and 0% in Group A, B, C and D, respectively, and those of LUNX mRNA were 44.4%, 69.7%, 10.0% and 0%, respectively, while the detection rate of CTCs was negative in all groups using simple ICC. There was a significant difference between the results obtained by lung cancer cell enrichment and detection kit and simple ICC method (P < 0.05), while no significant difference was found between the results obtained by lung cancer cell enrichment and detection kit and nested RT-PCR (P > 0.05). There was a significant difference in the detection rates of CK positive cells between group A and groups B, C, D (P < 0.05). The micrometastasis in peripheral blood was closely related with pathological types, cell differentiation and TNM staging (P < 0.05).
The lung cancer cell enrichment and detection kit developed by ourselves is a sensitive and reliable method to detect CTCs in patients with NSCLC. It may be helpful in diagnosis of NSCLC micrometastasis and circulating tumor cells in peripheral blood, re-determination of clinical stage and provide important information for cancer-therapy personalization.
探讨应用肺癌细胞免疫磁珠富集检测试剂盒检测非小细胞肺癌（NSCLC）患者外周血循环肿瘤细胞（CTC）的可行性及临床意义。
选取四组患者（A组：18例Ⅰ期肺癌患者；B组：33例Ⅱ - Ⅳ期肺癌患者；C组：20例良性肺疾病患者；D组：20名健康志愿者），采用自行研制的肺癌细胞富集检测试剂盒检测CTC，并与单纯免疫细胞化学（ICC）法及巢式聚合酶链反应（PCR）检测细胞角蛋白19（CK19）mRNA和肺癌相关转录因子（LUNX）mRNA的结果进行比较。
应用肺癌细胞富集检测试剂盒检测发现，A、B、C、D组CK阳性细胞检出率分别为33.3%、60.6%、0%、0%。采用巢式逆转录PCR（RT-PCR）检测，A、B、C、D组CK19 mRNA阳性表达率分别为38.9%、63.6%、20.0%、0%，LUNX mRNA阳性表达率分别为44.4%、69.7%、10.0%、0%，而单纯ICC法检测各组CTC均为阴性。肺癌细胞富集检测试剂盒与单纯ICC法检测结果差异有统计学意义（P < 0.05），与巢式RT-PCR检测结果差异无统计学意义（P > 0.05）。A组与B、C、D组CK阳性细胞检出率差异有统计学意义（P < 0.05）。外周血微转移与病理类型、细胞分化程度及TNM分期密切相关（P < 0.05）。
自行研制的肺癌细胞富集检测试剂盒是检测NSCLC患者CTC的一种灵敏、可靠的方法。有助于NSCLC微转移及外周血循环肿瘤细胞的诊断、临床分期的重新判定，并为肿瘤个体化治疗提供重要依据。
